Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Neoplasm Metastasis 3Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Castration Levels of Testosterone 1Carcinoma, Small Cell 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Carcinoma 1

Interventions

padeliporfin 4palladium-bacteriopheophorbide 1ixabepilone 1enzalutamide 1darolutamide 1apalutamide 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Docetaxel 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Genital Diseases, Male × apalutamide × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡